Intas Pharmaceutical has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard ...
The Print on MSN22h
How reciprocal Trump tariffs may impact Indian pharma, and become a bitter pill for the USSpooked by US president's threat, several Indian pharma players lobby for blanket duty waiver on drugs coming from America, ...
The pharma industry registered a 7.5% value growth year-on-year for the month of February, with sales of ₹18,781 crore, ...
Other unlisted companies that have been placed in the top 10 in the report in terms of valuation are Megha Engineering & Infrastructures, Parle Products, Intas Pharmaceuticals, Dream11 ...
Coherus BioSciences will see its workforce shrink once again as the result of the recently agreed sale of its Neulasta ...
Over the years, the broader pharmaceutical space has witnessed considerable interest from both strategic and institutional investors. For instance, Gujarat-based drugmaker Intas Pharmaceuticals Ltd, ...
Among them, the cardiac, gastrointestinal, and antidiabetic therapies saw high value growth of 9.5 per cent, 9.6 per cent, ...
The National Pharmaceutical Pricing Authority (NPPA) has notified the retail price of 53 new drugs based on applications submitted by individual companies, after finalising the same in the latest ...
Alvotech acquires Xbrane’s R&D operations and the biosimilar candidate XB003. Xbrane retains some pre-clinical development programs, that it intends to commercialize, and will continue operating as a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback